<DOC>
	<DOCNO>NCT00960336</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well doxorubicin hydrochloride liposome work first-line therapy treat old woman metastatic breast cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome First-Line Therapy Treating Older Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate effectiveness pegylated liposomal doxorubicin hydrochloride , term objective response rate , elderly woman metastatic breast cancer . Secondary - Determine feasibility drug patient . - Evaluate chemotherapy-induced toxicity patient . - Assess disease-free survival overall survival patient . - Study geriatric covariates . - Assess covariates predictive hematopoietic reserve risk febrile neutropenia patient . OUTLINE : This multicenter study . Patients receive pegylated liposomal doxorubicin hydrochloride IV 60-90 minute day 1 . Treatment repeat every 28 day 6 course absence unacceptable toxicity progressive disease . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive ductal lobular adenocarcinoma breast Metastatic disease confirm ≥ 1 following : Histology cytology Radiology Elevated CA 153 level No HER2/neu overexpression IHC FISH Measurable ( ≥ 10 mm ) evaluable disease Bone lesion isolate pleural effusion allow Hormone receptor status specify PATIENT CHARACTERISTICS : Postmenopausal Life expectancy &gt; 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Alkaline phosphatase ≤ 5 time ULN Bilirubin ≤ 2 time ULN Creatinine clearance ≥ 30 mL/min LVEF ≥ 50 % No congestive heart failure uncontrolled cardiac disease No malignancy within past 5 year except curatively treat carcinoma situ cervix , urothelial situ carcinoma , basal cell cancer No prior hypersensitivity anthracyclines No psychological , familial , social , geographical reason would preclude study followup No serious illness physical mental condition result permanent disability may preclude successful treatment PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy allow No development metastatic disease within 6 month completion adjuvant anthracyclinebased chemotherapy No 300 mg/m² prior doxorubicin hydrochloride 600 mg/m² prior epirubicin hydrochloride adjuvant set More 30 day since prior participation another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
</DOC>